Search

Displaying results 5491 - 5500 of 6278 in total
  1. Drug

    Rolicyclidine

    go.drugbank.com/drugs/DB01549
    ExperimentalIllicit

    It also has hallucinogenic and sedative properties.

  2. Drug

    Quisqualic acid

    go.drugbank.com/drugs/DB02999
    Experimental

    Quisqualic acid is an agonist at two subsets of excitatory amino acid receptors, ionotropic receptors that directly control membrane channels and metabotropic receptors that indirectly mediate calcium

  3. Drug

    Methyl-1-testosterone

    go.drugbank.com/drugs/DB01572
    ExperimentalIllicit

    It is a derivative of 1-testosterone with a methyl group in the carbon 17. Methyl-1-testosterone is considered a prohibited doping substance.

    Synonyms: (5α,17β)-17-Hydroxy-17-methylandrost-1-en-3-one, 17alpha-Methyl-17beta-hydroxy-5alpha-androst-1-en-3-one
  4. Drug

    Methoxy arachidonyl fluorophosphonate

    go.drugbank.com/drugs/DB02465
    Experimental

    It inhibits phospholipase A2 and fatty acid amide hydrolase with special potency, displaying IC50 values in the low-nanomolar range.

  5. Drug

    CYT007-TNFQb

    go.drugbank.com/drugs/DB05758
    Experimental

    CYT007-TNFQb is an active immunization therapy that aims at providing a novel treatment to people suffering from RA or psoriasis.

  6. Drug

    rhIGFBP-3

    go.drugbank.com/drugs/DB05897
    Investigational

    It is developed by Insmed and is currently under phase I of the clinical trial.

  7. Drug

    Friulimicin B

    go.drugbank.com/drugs/DB06087
    Investigational

    It shows strong cidal activity against a number of Gram-positive pathogens which commonly cause serious infections in hospital patients and which are becoming more routinely acquired in the community.

  8. Drug

    alpha-Hydroxy glycineamide

    go.drugbank.com/drugs/DB06568
    Experimental

    It also has an effect on viral gp160 envelope protein. [A31692]

  9. Drug

    Gavestinel

    go.drugbank.com/drugs/DB06741
    Experimental

    Highly potent and selective non-competitive antagonist acting at the strychnine-insensitive glycine binding site of the NMDA receptor-channel complex (Kd = 0.8 nM).

  10. Drug

    AdimrSC-2f

    go.drugbank.com/drugs/DB16436
    Investigational

    The AdimrSC-2f (SARS-CoV-2) vaccine is developed through Adimmune Corporation, the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia[L30553].